- News
- Market Watch
- Bursa Malaysia
- My Portfolio
- Exchange Rates
- Unit Trusts
- Market Intelligence
- IPO Watch
- Company Ratings
- Bonus & Dividends
- Financial Results
- Share Buybacks
- Changes in Shareholdings
- Currency Converter
- Investor Relations
- Maritime
Wednesday November 4, 2009
Novartis to buy majority in China's Tianyuan US$125mil
BASEL, Switzerland: Pharmaceuticals company Novartis AG said Wednesday it is paying US$125 million for an 85 percent stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
Privately-held Tianyuan sells vaccines against diseases such as hemorrhagic fever with renal syndrome, or HFRS, caused by hantaviruses, and conducts research into "various preventable viral and bacterial diseases," Novartis said.
The Chinese company had net sales of $25 million in 2008.
The deal, which requires regulatory approval, comes a day after Novartis announced it will invest some $1.25 billion in its research centers in China over the next five years. - AP
- EPF’s 2009 payout will be better
- How to improve your investment skills
- Google opens new social hub in face-off with Facebook
- Billionaire Buffett says bailout money will be paid back
- Honda expands airbag inflation recall
- KNM’s future needs may be more than RM3.4bil
- US stocks up, Dow up above 10,000 again
- Bank Negara said to have rejected Mulpha’s application
- Toyota seeks damage control, in public and private
- US$1b JV smelter for Sarawak
- How to improve your investment skills
- SingTel to buy way to growth
- Maybank Q2 earnings up 35% to RM993mil
- US stocks up, Dow up above 10,000 again
- Google opens new social hub in face-off with Facebook
- BCorp unit plans RM180mil solar photovoltaic power plant
- P1 sees more competitive prices for WiMAX services
- UBS returns to profit in 4th quarter
- Macquarie Q2 profit forecast disappoints
- Ekuinas eyes minimum IRR of 12% a year
RSS